Latest Capital Raising And Funding News

Western Gold Resources reports promising early drilling results and a significant upgrade to its Gold Duke Project economics, supported by a $6.75 million capital raise to fund production.

Siren Gold Limited has bolstered its leadership and financial position while delivering encouraging exploration results across its New Zealand gold and antimony projects, setting the stage for resource expansion and development progress.

Godolphin Resources has reported a substantial upgrade to its Lewis Ponds gold, silver, and base metals resource, alongside successful capital raising to fund ongoing development and exploration.

Macro Metals Limited has bolstered its financial position with a $2 million capital raise while making significant progress across its iron ore and construction sand projects, underpinned by strong Indigenous joint ventures and mining services development.

Savannah Goldfields is on the cusp of restarting gold production at its Georgetown plant, backed by promising exploration results and a $15 million capital raise to fund growth and debt repayment.

Rokeby Resources has confirmed significant gold and antimony mineralisation across multiple prospects at its Hurricane Project in North Queensland, following its maiden drilling campaign. The company secured $1.7 million in an oversubscribed placement to advance Phase 2 drilling and exploration.

Locksley Resources has made significant strides in its US critical minerals strategy, advancing proprietary antimony refining technology and expanding its Mojave Project landholding. The company also completed an oversubscribed capital raise to fund upcoming drilling and downstream processing initiatives.

Hillgrove Resources has accelerated production at its Nugent centre ahead of schedule, driving an 8% rise in copper output and reducing costs. A $28 million capital raise will fund further development and exploration, underpinning growth prospects.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches AI-driven PolePilot™ to boost productivity and ARPU.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Orion Minerals reported a net cash outflow of A$3.1 million for the September 2025 quarter but has secured an $8.6 million capital raise post-quarter to support ongoing project development and operations.